337 related articles for article (PubMed ID: 32552251)
1. Pathological Role of Receptor for Advanced Glycation End Products in Calcified Aortic Valve Stenosis.
Saku K; Tahara N; Takaseya T; Otsuka H; Takagi K; Shojima T; Shintani Y; Zaima Y; Kikusaki S; Fukuda T; Oryoji A; Nishino Y; Matsui T; Kakuma T; Akiba J; Fukumoto Y; Yamagishi SI; Tanaka H
J Am Heart Assoc; 2020 Jul; 9(13):e015261. PubMed ID: 32552251
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end product-modified low-density lipoprotein promotes pro-osteogenic reprogramming via RAGE/NF-κB pathway and exaggerates aortic valve calcification in hamsters.
Yang X; Zeng J; Xie K; Su S; Guo Y; Zhang H; Chen J; Ma Z; Xiao Z; Zhu P; Zheng S; Xu D; Zeng Q
Mol Med; 2024 Jun; 30(1):76. PubMed ID: 38840067
[TBL] [Abstract][Full Text] [Related]
4. RAGE deficiency alleviates aortic valve calcification in ApoE
Wang B; Cai Z; Liu B; Liu Z; Zhou X; Dong N; Li F
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):781-792. PubMed ID: 28024939
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.
Wei Q; Ren X; Jiang Y; Jin H; Liu N; Li J
BMC Cardiovasc Disord; 2013 Mar; 13():13. PubMed ID: 23497312
[TBL] [Abstract][Full Text] [Related]
6. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.
Basta G; Corciu AI; Vianello A; Del Turco S; Foffa I; Navarra T; Chiappino D; Berti S; Mazzone A
Atherosclerosis; 2010 Jun; 210(2):614-8. PubMed ID: 20074734
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products.
Li F; Cai Z; Chen F; Shi X; Zhang Q; Chen S; Shi J; Wang DW; Dong N
Basic Res Cardiol; 2012 Nov; 107(6):306. PubMed ID: 23070070
[TBL] [Abstract][Full Text] [Related]
8. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement.
Yeghiazaryan K; Skowasch D; Bauriedel G; Schild H; Golubnitschaja O
Amino Acids; 2007 Jan; 32(1):109-14. PubMed ID: 16874466
[TBL] [Abstract][Full Text] [Related]
9. Role for Galectin-3 in Calcific Aortic Valve Stenosis.
Sádaba JR; Martínez-Martínez E; Arrieta V; Álvarez V; Fernández-Celis A; Ibarrola J; Melero A; Rossignol P; Cachofeiro V; López-Andrés N
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27815266
[TBL] [Abstract][Full Text] [Related]
10. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
11. Age, Sex, and Valve Phenotype Differences in Fibro-Calcific Remodeling of Calcified Aortic Valve.
Voisine M; Hervault M; Shen M; Boilard AJ; Filion B; Rosa M; Bossé Y; Mathieu P; Côté N; Clavel MA
J Am Heart Assoc; 2020 May; 9(10):e015610. PubMed ID: 32384012
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis.
Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A
J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and nitric oxide pathway in adult patients who are candidates for cardiac surgery: patterns and differences.
Cavalca V; Tremoli E; Porro B; Veglia F; Myasoedova V; Squellerio I; Manzone D; Zanobini M; Trezzi M; Di Minno MN; Werba JP; Tedesco C; Alamanni F; Parolari A
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):923-30. PubMed ID: 24014619
[TBL] [Abstract][Full Text] [Related]
14. Association of Time Between Left Ventricular and Aortic Systolic Pressure Peaks With Severity of Aortic Stenosis and Calcification of Aortic Valve.
Sato K; Kumar A; Jobanputra Y; Betancor J; Halane M; George R; Menon V; Krishnaswamy A; Tuzcu EM; Harb S; Jaber WA; Mick S; Svensson LG; Kapadia SR
JAMA Cardiol; 2019 Jun; 4(6):549-555. PubMed ID: 31042265
[TBL] [Abstract][Full Text] [Related]
15. Clinical and hemodynamic results after direct transcatheter aortic valve replacement versus pre-implantation balloon aortic valvuloplasty: A case-matched analysis.
Ferrera C; Nombela-Franco L; Garcia E; Jimenez-Quevedo P; Biagioni C; Gonzalo N; Nuñez-Gil I; Viana-Tejedor A; Salinas P; Alberto de Agustin J; Almeria C; Islas F; Perez de Isla L; Fernandez-Perez C; Escaned J; Fernández-Ortiz A; Macaya C
Catheter Cardiovasc Interv; 2017 Nov; 90(5):809-816. PubMed ID: 27515377
[TBL] [Abstract][Full Text] [Related]
16. Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients.
Zheng H; Li Y; Xie N; Huang JL; Xu HF; Luo M
Genet Mol Res; 2015 Apr; 14(2):3775-83. PubMed ID: 25966147
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
18. Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks.
Pasipoularides A
J Cardiovasc Transl Res; 2016 Apr; 9(2):102-18. PubMed ID: 26891845
[TBL] [Abstract][Full Text] [Related]
19. Valvular osteoclasts in calcification and aortic valve stenosis severity.
Nagy E; Eriksson P; Yousry M; Caidahl K; Ingelsson E; Hansson GK; Franco-Cereceda A; Bäck M
Int J Cardiol; 2013 Oct; 168(3):2264-71. PubMed ID: 23452891
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study.
Koos R; Brandenburg V; Mahnken AH; Schneider R; Dohmen G; Autschbach R; Marx N; Kramann R
J Heart Valve Dis; 2013 May; 22(3):317-25. PubMed ID: 24151757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
